|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1341 G street NW Flr 5 |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 61458-1406
|
||||||||
|
6. House ID# 353940050
|
TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Robert Raben |
Date | 1/18/2018 2:38:40 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Consumer Product Safety Commission (CPSC), Natl Institutes of Health (NIH), Environmental Protection Agency (EPA), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katharine |
Huffman |
|
|
|
Anais |
Duran |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Consumer Product Safety Commission (CPSC), Natl Institutes of Health (NIH), Environmental Protection Agency (EPA), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katharine |
Huffman |
|
|
|
Anais |
Duran |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Consumer Product Safety Commission (CPSC), Natl Institutes of Health (NIH), Environmental Protection Agency (EPA), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katharine |
Huffman |
|
|
|
Anais |
Duran |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Consumer Product Safety Commission (CPSC), Natl Institutes of Health (NIH), Environmental Protection Agency (EPA), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katharine |
Huffman |
|
|
|
Anais |
Duran |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |